Micro Medical Solutions announces addition of new Chief Medical Officer

Wilmington MA, February 2016—Micro Medical Solutions, a pioneer in interventional innovation in the treatment of critical limb ischemia (CLI), today announced that one of the most respected experts in the treatment of peripheral artery disease (PAD) and CLI, Dr. Jihad Mustafa, M.D., has joined the company as Chief Medical Officer. Dr. Mustapha is a global thought leader for the treatment of patients with CLI, as well as amputation prevention. Dr. Mustapha is a board-certified interventional cardiologist specializing in minimally invasive, non-surgical therapy. He has advanced training in coronary stent and complex peripheral vascular disease treatments including laser, atherectomy, and totally occluded arteries. Dr. Mustapha graduated from Wayne State University and St. George University School of Medicine, performed his medical residency at Spectrum Health Hospital in Grand Rapids, Mich., and completed Fellowships in both Cardiology and Interventional Cardiology at Louisiana State University School of Medicine.

Along with his position as CMO of Micro Medical Solutions, Dr. Mustapha is currently in practice at the Heart & Vascular Center at Metro Health Hospital in Wyoming, Mich., where he is the Director of Endovascular Interventions. Dr. Mustapha is the Founder and Director of the Amputation Prevention Symposium (AMP) and the co-director of the West Michigan Save a Leg, Save a Life Chapter. He has multiple publications, including those on critical limb ischemia and amputation prevention. He has a special interest in medical device inventions and holds several patents.

“Dr. Mustafa’s mission and passion align perfectly with ours,” says Gregory Sullivan, CEO of Micro Medical Solutions. “He is one of the most respected experts in the field, and joining as Chief Medical Officer at this juncture speaks volumes about his commitment and dedication to inspire better CLI intervention. Dr. Mustafa’s passion to prevent amputations due to CLI by improving BTK intervention is second to none. Together we plan to be on the forefront of the movement to improve outcomes for CLI patients.”

CONTACT: Peg Thornton, Director of Corporate and Market Development, Micro Medical Solutions 732-616-9123

About CLI

Peripheral artery disease (PAD) and critical limb ischemia (CLI) affected 215 million people worldwide in 2015, predicted to be 230 million by 2020.1 CLI currently afflicts 2.8 to 3.5 million of those with PAD and is projected to rise to 4.5 to 5.6 million.2 Rates of amputations in the general population with PAD are declining, but amputations in CLI continue to escalate. It has been estimated that 25% of CLI patients will undergo major amputation. Prognosis with respect to limb preservation in CLI patients is poor, particularly in no-option CLI patients, where six-month major amputation rates have been reported to be as high as 50%.3 If something doesn’t change, the number of amputations due to CLI could exceed one million by 2030.

References: 1. Global Peripheral Artery Disease Market: Trends & Opportunities (2015-2020), February 2016 (Page 19). Daedal Research Group. 2. Critical Limb Ischemia. Volume 1 United States Epidemiology, 2010. Accessed at[orts/cliepiusreprot.php., October 14, 2016. 3. Teraa M, Conte MS, Moll FL, Verhaar MC. Contemporary Reviews: Critical Limb Ischemia: Current Trends and Future Directions. J Am Heart Assoc 2016; 5: e002938.

Back To Top